This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
esophageal-cancer
Esophageal Cancer
Esophageal cancer includes ESCC (squamous, smoking/alcohol) and EAC (adenocarcinoma, Barrett's/HER2+ ~15%); nivolumab+chemotherapy (CheckMate 648) is first-line for ESCC; trastuzumab+chemotherapy (ToGA) and T-DXd for HER2+ EAC; 5-year OS ~20%.
Entry Metadata
| Field | Value |
|---|---|
| ID | esophageal-cancer |
| Name | Esophageal Cancer |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449-462. · PubMed 35108470
- Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506-1517. · PubMed 31582355